[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"herpes-zoster-hz\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:herpes-zoster-hz":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,65,98,128,150,173,197,219],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100372345","phase-3-shingrix-in-renal-transplant-recipients-100372345",false,"NCT04128189","Shingrix in Renal Transplant Recipients","Safety and Immunogenicity of Shingrix in Renal Transplant Recipients","Study Population:\n\nAdults with chronic kidney failure who are listed for kidney transplantation at participating transplant centers.\n\nInclusion Criteria:\n\nAge 18 to 70 years Able and willing to provide written informed consent Currently on the waiting list for kidney transplantation at a participating institution, with anticipated transplantation occurring between \\>3 and 24 months after the first dose of Shingrix\n\nEither:\n\nEligible to receive Shingrix at study entry per CDC-recommended schedule, or Previously completed the Shingrix vaccination series within 3 to 24 months prior to study entry Female participants of non-childbearing potential (e.g., tubal ligation, hysterectomy, ovariectomy, or post-menopausal ≥12 months)\n\nFemale participants of childbearing potential must:\n\nUse adequate contraception for at least 30 days prior to vaccination Have a negative pregnancy test on the day of each vaccination Agree to continue adequate contraception during the study and for 2 months after completing the vaccination series Be considered by the investigator likely to comply with study requirements\n\nExclusion Criteria:\n\nActive immunosuppressive or immunodeficient condition (e.g., malignancy, HIV infection) or receipt of immunosuppressive therapy within 3 months prior to planned vaccination that, in the investigator's opinion, may interfere with vaccine response History of herpes zoster (shingles) within the past 3 years Receipt of varicella vaccine within 3 years prior to study entry Known allergy to any component of the Shingrix vaccine Receipt of investigational drugs within 30 days prior to enrollment or planned use during the study Receipt of non-live vaccines within 2 weeks prior to any Shingrix dose or planned within 30 days after vaccination Receipt of live vaccines within 4 weeks prior to any Shingrix dose or planned within 30 days after vaccination Pregnant or breastfeeding Planned or prior multi-organ transplantation Residence or travel distance greater than 2 hours from the study site, which would interfere with study visits or timely processing of blood samples","ALL","18 Years","70 Years",{"count":20,"type":21},132,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this clinical trial is to learn how well the shingles vaccine (Shingrix) works and how safe it is in adults with kidney failure who are waiting for a kidney transplant, including those who later receive a transplant. The study also aims to find out whether giving an extra (third) dose of the vaccine after transplant improves protection.\n\nThe main questions it aims to answer are:\n\nHow strong is the body's immune response to the vaccine at different time points (about 1 month, 2 years, and 3 years after vaccination) in people waiting for a kidney transplant?\n\nDoes a third dose of the vaccine after transplant improve the immune response compared to not receiving a third dose?\n\nHow long does protection from the vaccine last before and after transplant?\n\nHow safe is the vaccine in this group, including whether it affects transplant-related immune markers?\n\nResearchers will compare people who receive a third dose of the vaccine after transplant to those who do not receive a third dose, as well as to results from similar groups studied in the past, to see if the extra dose improves immune protection.\n\nParticipants will:\n\nBe screened to see if they can take part in the study Attend about 3 to 6 study visits over approximately 30 to 37 months Receive two doses of the shingles vaccine if they have not already been vaccinated, or complete study assessments if they were vaccinated before joining\n\nIf they receive a kidney transplant during the study, be randomly assigned (by chance) to receive either a third dose of the vaccine or no additional dose\n\nComplete questionnaires, have physical exams if needed, and provide blood (and urine, if applicable) samples at study visits\n\nTake part in follow-up visits to check immune response and safety, with the option to allow samples to be stored for future research\n\nShingrix is approved for adults aged 50 and older and for younger adults with weakened immune systems. However, giving a third dose after a kidney transplant is not standard practice and is being studied in this trial.",[27,28,29,30,31],"Kidney Transplant Recipient Response to Shingrix Vaccine","Kidney Failure","Kidney Failure, Chronic","Kidney Transplantation","Herpes Zoster (HZ)",[33,34,35,36,37,28,38,39,40,41,42,43,44,45,46,47,48,49,50,51],"Shingrix","Recombinant Zoster Vaccine","Herpes Zoster Vaccine","Herpes Zoster","Shingles","Chronic Kidney Disease","Renal Failure","Kidney Transplant","Renal Transplantation","Transplant Candidates","Immunocompromised","Immunogenicity","Vaccine Response","Cellular Immunity","T Cell Response","Booster Dose","Vaccine Durability","Post-Transplant Immunity","Vaccine Safety","RECRUITING","2026-04-02",{"date":55,"type":56},"2026-04-08","ACTUAL",{"date":58,"type":56},"2023-03-02",{"date":60,"type":21},"2029-06",{"name":62,"class":63},"University of Colorado, Denver","OTHER",4,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100587756","phase-1-a-study-to-evaluate-the-safety-of-recombinant-herpes-zoster-vaccine-for-healthy-individuals-100587756","NCT06932523","A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals","Randomized, Blinded, Controlled Phase I\u002FⅡ Clinical Trial Evaluating the Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) for Healthy Individuals Aged 40 Years and Above","Inclusion Criteria:\n\n* Age ≥ 40 years old on the day of enrollment, gender not limited.\n* Can provide legal proof of identity.\n* Be able to understand the experimental procedure and sign a written informed consent form, expressing agreement to participate in the experiment.\n* Be able to participate in all planned follow-up visits and comply with all trial procedures.\n* On the day of enrollment, the body temperature was less than 37.3 ℃ (axillary temperature).\n* Chronic disease patients need to be in a stable period of chronic disease.\n* Female and male participants of childbearing age agreed to adopt strict and effective contraceptive measures from the start of the trial to 6 months after full exemption.\n\nExclusion Criteria:\n\n* Individuals with a history of herpes zoster in the past.\n* Individuals with a history of vaccination against chickenpox or shingles.\n* Individuals who have had close contact with patients with chickenpox or shingles in the past 2 years.\n* Women of childbearing age who have a positive urine pregnancy test, are breastfeeding, pregnant, or plan to become pregnant within 6 months after the start of the test and the full exemption period.\n* Individuals who are allergic to any component of the vaccine or have a history of other severe allergies.\n* Use immunoglobulin and\u002For any blood products within 3 months prior to administering the trial vaccine, or plan to use them during the trial period.\n* Have taken antipyretic, analgesic, or anti allergic drugs within 72 hours prior to receiving the experimental vaccine.\n* Any experimental or unregistered product (drug, vaccine, biological product or device) other than the experimental vaccine has been used within one month prior to vaccination, or is planned to be used during the trial period.\n* Administer non live vaccines within 7 days prior to administering the experimental vaccine or live vaccines within 14 days prior to administering the experimental vaccine.\n* Suffering from a serious illness that prevents the completion of the entire experiment.\n* Received immunosuppressive therapy or other immunomodulatory drugs, monoclonal antibodies, thymosin, interferon, etc. within 6 months prior to vaccination with the experimental vaccine, or planned to receive such treatment within 1 month after the first dose to full immunization, but local medication is allowed.\n* Chemotherapy, radiotherapy, and organ and bone marrow transplantation related treatments for cancer or other diseases.\n* Diseases or medical measures that lead to immune dysfunction\n* Individuals currently suffering from serious infectious diseases such as active tuberculosis and active viral hepatitis.\n* Moderate or severe acute illness\u002Finfection, or febrile illness within 72 hours prior to vaccination.\n* Known to have a history of thrombocytopenia, any coagulation dysfunction, or being treated with anticoagulants.\n* Suffering from serious cardiovascular disease, pulmonary edema, serious liver and kidney disease, and diabetes that cannot be controlled by drugs.\n* Previous history of mental and neurological disorders or family history of mental illness.\n* Currently suffering from various severe infectious, suppurative, and allergic skin diseases.\n* Plan to move before the end of the trial or leave the local area for a long time during the scheduled trial visit.\n* (Phase I ) Abnormal blood routine, blood biochemistry, coagulation, and urine routine indicators before vaccination (excluding those judged by doctors to have no clinical significance).\n* Any situation that the researcher believes may affect the evaluation of the experiment.",true,"40 Years",{"count":75,"type":21},645,[77,78],"PHASE1","PHASE2","The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above. This study will be conducted in 2 substudies: Substudy A (Phase I) and Substudy B (Phase Ⅱ).",[31],[82,83,84,85,86],"herpes zoster","recombinant herpes zoster vaccine","vaccine","safety","immunogenicity","2026-01-05",{"date":89,"type":56},"2026-01-07",{"date":91,"type":56},"2025-04-04",{"date":93,"type":21},"2027-12-31",{"name":95,"class":96},"Shanghai Institute Of Biological Products","INDUSTRY",1,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":72,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100585493","a-study-that-collects-participant-data-and-biospecimens-to-analyze-pathogenic-exosomes-that-mediate-increased-vascular-dementia-risk-in-individuals-with-herpes-zoster-100585493","NCT06903078","A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.","Pathogenic Exosomes During Herpes Zoster Mediate Increased Vascular Dementia Risk.","R01","Inclusion Criteria:\n\nAt the Screening Visit (Visit 1\u002FDay 1), all participants must meet all the following criteria in order to be considered for participation in the study:\n\n1. Be a male or female ≥ 18 years of age.\n2. Present to clinic for routine dermatologic evaluation with or without rash.\n3. Are willing and able to complete study visits and procedures, and able to effectively communicate with the investigator and other study personnel.\n4. Have adequate venous access and are willing to undergo venipuncture for blood draws.\n5. Able to provide written informed consent prior to any study procedures. Additional inclusion criteria for Herpes zoster (HZ) participants,\n6. Present with acute, vesicle-stage HZ that has not been treated with antiviral therapies\n7. Are willing and have reliable transportation to complete additional follow-up visits at 7 days, 1 month, 3 months, 6 months, and 12 months after initial visit for acute HZ.\n\nExclusion Criteria:\n\nAt the Screening Visit (Visit 1\u002FDay 1), participants meeting any of the following criteria will be excluded from participation in the study:\n\n1. Female individuals who are pregnant or breast-feeding.\n2. Receiving systemic or topical antivirals for varicella zoster virus (VZV).\n3. Sensitivity or allergy to systemic or topical antiviral medications for HZ.\n4. History of diagnosed HZ within the last 8 years.\n5. Received a HZ vaccine (e.g., Zostavax®\u002FShingrix®) within the last 8 years.\n6. Received any vaccinations within the last 3 months.\n7. Currently taking immunosuppressive therapies, including medications and radiation.\n8. Currently taking any anticoagulants.\n9. History of any coagulation disorder(s).\n10. History of end-stage renal disease or uremia.\n11. History of end-stage liver disease.\n12. History of HIV.\n13. Have had a COVID-19 infection in last 3 months.\n14. Any history of non-skin cancers within the last 3 months.\n15. History of serious infection requiring hospitalization in the last 3 months.\n16. Prior history of cardiovascular accident or myocardial infarction within the last 12 months.\n17. Prior cerebrovascular accident in the past 12 months.",{"count":107,"type":21},375,"OBSERVATIONAL","The purpose of this observational research study is to study if patients with herpes zoster, also known as Shingles, have a higher risk of vascular dysfunction (problems with blood vessels, including stroke) and vascular dementia (problems with mental decline as a result of decreased blood flow to the brain) compared to patients without herpes zoster.\n\nPatients are evaluated based on the group they are assigned too:\n\n1. Herpes Zoster (HZ) Group: individuals presenting with untreated herpes zoster. These participants will have 6 visits:\n\n   * Day 1 = 1st day presenting to clinic with acute zoster\n   * 7 days post zoster\n   * 1 month after Day 1\n   * 3 months after Day 1\n   * 6 months after Day 1\n   * 12 months after Day 1\n2. Control Group: individuals without herpes zoster o Day 1 (only 1 visit will be completed)\n\nThis study does not have a study medication\u002Fdevice. Standard of care for all patients will be followed.",[31,111],"Vascular Dementia",[113,114,36,37,115,116,117],"RO1","1R01AG085406-01","Dr. Stephen Tyring","Dementia risk HZ","VZV","2025-12-04",{"date":120,"type":56},"2025-12-11",{"date":122,"type":56},"2025-02-13",{"date":124,"type":21},"2030-08",{"name":126,"class":63},"Center for Clinical Studies, Texas",2,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":97},"100591266","phase-2-clinical-study-on-the-treatment-of-herpes-zoster-pain-with-dexmedetomidine-combined-with-long-term-high-voltage-100591266","NCT06978192","Clinical Study on the Treatment of Herpes Zoster Pain With Dexmedetomidine Combined With Long-term High Voltage","The Clinical Efficacy Analysis of Long-Duration High-Voltage Pulsed Radiofrequency Combined With Dexmedetomidine Nasal Spray in the Treatment of Herpes Zoster-Associated Neuropathic Pain","Inclusion Criteria:\n\n* Patients with adverse reactions that are not effective in conventional drug treatment and cannot tolerate drugs\n* The pain is located in the corresponding innervated are\n* The pain affects the patient's daily life or work\n* Diagnostic nerve block is effective and pain limited\n* Recurrent herpes zoster pain\n* Patients with shingle-related pain aged 40-85 years\n\nExclusion Criteria:\n\n* Infection at the puncture site, systemic infection that may spread, and malignant tumors near the puncture\n* There are contraindications in minimally invasive interventional therapy such as coagulation function and platelet dysfunction\n* Allergies to local anesthetics and inhalants\n* Heart, lung, liver, kidney and other important organ failure, can not tolerate surgery\n* Severe endocrine system diseases or long-term use of hormone or immunosuppressive therapy\n* Patients with cardiac pacemakers, pregnant or lactating women\n* Patients with cognitive dysfunction or poor coordination\n* Patients who have been treated with electrical stimulation or PRF","85 Years",{"count":137,"type":21},92,[78],"Participants will be invited to take part in clinical research. This informed consent form will provide information to the participants to help them decide whether to participate in the clinical study. If participants have any questions, please ask them directly to the researcher in charge of this study. This study was approved by the Biomedical Research Ethics Review Committee of the Institute. This trial is a randomized controlled clinical study. According to the different treatment methods, the control group was randomly divided into the control group and the experimental group. Control group: On the basis of conventional drug treatment, long-term high-voltage pulsed radiofrequency treatment was carried out. Experimental group: On the basis of conventional drug treatment, dexmedetomidine nasal spray was administered before HL-PRF treatment, before bedtime on the day of the operation, and before bedtime on the 1st to 3rd days after the operation. Heart rate, blood pressure and blood oxygen saturation were monitored respectively before the operation, during the operation and after the operation. Telephone follow-ups were conducted at 1 week, 1 month, 3 months and 6 months after the operation respectively. If the participants agree to participate in this study, the researchers will number the participants and establish medical records. The researchers will have detailed communication with the participants or their families, inform them of the research situation, and ask the participants to provide disease information, including the onset of the disease, family history, previous medical visits and some examination results.\n\nWhat do you need to do in this research? Once participating in the study, participants will be required to provide true information about their medical history and current physical condition. Tell the research doctor about any discomfort you encountered during the research process; Do not take restricted drugs, foods, etc. Tell the research doctor whether you have participated in or are currently participating in any other research recently.\n\nRisks and discomfort: Communicating and talking with researchers may cause participants to feel psychologically uncomfortable.\n\nSince this study only collected the medical history, data and epidemiological investigation of patients or normal people, there is no harm in this study. If participants are injured during the clinical trial, they can receive free treatment and\u002For appropriate compensation in accordance with Chinese law.\n\nWhat are the benefits of participating in this research? Useful information can be provided for disease research by studying the information of the participants.\n\nThe cost of participating in this study: Participation in this study will be based on the medical information of the research participants, and the related costs will not be borne by the participants.\n\nPrivacy issue: If participants decide to take part in this study, their participation status and personal data during the study period will be kept confidential. When necessary, government administrative departments or members of the ethics review committee may access the personal data of participants in research institutions. When the results of this study are announced, the personal identity information of the participants will not be disclosed.",[31],"2025-05-14",{"date":143,"type":56},"2025-05-18",{"date":145,"type":56},"2024-12-16",{"date":147,"type":21},"2026-05-31",{"name":149,"class":63},"Fenghui Deng",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":97},"100590592","comparative-efficacy-of-pregabalin-and-lacosamide-in-patients-with-herpes-zoster-and-post-herpetic-neuralgia-100590592","NCT06969417","Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia","Inclusion Criteria:\n\n* Diagnosed cases of herpes zoster suffering from postherpetic neuralgia\n* Ages: 18 to 50\n* Both male and female\n\nExclusion Criteria:\n\n* Lack of consent\n* Patient already taking pain killers for post herpetic neuralgia\n* Patients suffering from other systemic illness","50 Years",{"count":158,"type":21},50,[160],"NA","Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). PHN is characterized by neuropathic pain lasting beyond the resolution of the rashes. Post herpetic neuralgia (PHN) represents a potentially debilitating and often undertreated form of neuropathic pain that disproportionately affects vulnerable populations, including the elderly and the immunocompromised. PHN pain is typically localized, unilateral and chronic, but may be constant, intermittent, spontaneous and\u002For evoked. PHN is likely to interfere with sleep and daily activities.\n\nPregabalin is a gabapentinoid licenced for treatment of neurological disorders. It is one of the earlier drugs approved by the US Food and Drug Administration (2004) for the treatment of painful diabetic neuropathy and postherpetic neuralgia (PHN). Lacosamide (LCM) was approved in 2008 in the European Union and in the United States as adjunctive therapy for the treatment of focal-onset seizures with or without secondary generalization in adults and adolescents with epilepsy. Its efficacy has also been proven in neuropathic pain.\n\nAlthough Pregabalin and Lacosamide have proven effective in various neuropathic pain disorder, comparative studies specifically for PHN remain scarce. This study aims to compare the efficacy of Pregabalin and Lacosamide in PHN patients, addressing the current gap in literature and providing clinically relevant insights to optimize treatment selection.",[31,163],"Post Herpetic Neuralgia (PHN)","2025-05-13",{"date":141,"type":56},{"date":167,"type":56},"2025-04-10",{"date":169,"type":21},"2025-09-30",{"name":171,"class":172},"CMH Kharian Medical College","OTHER_GOV",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":72,"sex":16,"minAge":73,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":97},"100583324","phase-1-safety-and-immunogenicity-of-the-recombinant-zoster-vaccine-lyb004-in-adults-aged-40-years-and-older-100583324","NCT06874842","Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older","A Phase I, Randomized, Observer-blinded, Parallel-Controlled, Dose Escalation Clinical Trial to Assess the Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older","Inclusion Criteria:\n\n1. Residents aged 40 years and older (at the time of screening), regardless of gender;\n2. Participants can provide valid identification, voluntarily agree to participate in the study, and sign the Informed Consent Form;\n3. Participants are able to attend all planned follow-up visits and comply with the protocol requirements;\n4. Females of childbearing potential should use effective contraceptive measures one month before enrollment; females of childbearing potential (excluding those who have undergone tubal ligation, bilateral oophorectomy, or hysterectomy) and male participants should practice effective contraception and avoid pregnancy plans, as well as sperm or egg donation plans from the time of enrollment until 6 months after the full course of vaccination. Effective contraceptive methods include oral contraceptives (excluding emergency contraceptives), injectable or implantable contraceptives, sustained-release local contraceptives, contraceptive patches, intrauterine devices, sterilization, abstinence, condoms, diaphragms, cervical caps, etc.\n\nExclusion Criteria:\n\n1. Axillary temperature ≥ 37.3°C;\n2. History of herpes zoster before vaccination with the investigational vaccine;\n3. Previous vaccination against HZ or varicella;\n4. Has had close contact with patients with varicella\u002Fherpes zoster within 6 months before vaccination with the investigational vaccine;\n5. Has received any vaccine within 14 days before vaccination, or have received a live vaccine within 28 days;\n6. Have been injected with gamma globulin or intravenous immunoglobulin within 3 months before vaccination;\n7. Individual with the following diseases: ① Have acute diseases or are in the acute exacerbation period of chronic diseases, or take antipyretic, analgesic, and anti-allergic drugs within 3 days before vaccination; ② Allergies to any component of the study vaccine, or have a history of severe allergic reactions to any vaccination; ③ History of convulsions, epilepsy, encephalopathy (such as congenital brain dysplasia, brain trauma, brain tumors, cerebral hemorrhage, cerebral infarction, brain infection, chemical poisoning, etc. causing brain nerve tissue damage, etc.) and mental illness, or a family history of mental illness; ④ Asplenia, or functional asplenia; ⑤Primary or secondary immunodeficiency, or diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune diseases; ⑥ Chronic administration (≥14 consecutive days) of glucocorticoid (reference value for dose: ≥ 2mg\u002Fkg\u002Fday or ≥ 20mg\u002Fday prednisone or equivalent) or other immunosuppressive agents within the past 3 months, with the exception of inhaled or topical steroids, or short-term use (\\\u003C14 consecutive days) of oral corticosteroids; ⑦ Severe cardiovascular diseases (pulmonary heart disease, pulmonary edema, etc.), severe liver and kidney diseases, complicated diabetes; ⑧ History of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection;⑨Severe hypertension that cannot be controlled by medication (on-site measurement: systolic blood pressure ≥ 140mmHg and\u002For diastolic blood pressure ≥ 90mmHg);\n8. Abnormal laboratory test indicators specified in the protocol before vaccination and determined by the clinical investigator to be of clinical significance;\n9. History of long-term alcohol abuse and\u002For drug abuse;\n10. Individual who is currently participating in other research or unregistered product (drugs, vaccines, or devices, etc.) clinical studies, or plan to participate in other clinical studies before the end of this clinical study;\n11. Exclusion criteria for specific populations: lactating or pregnant women during the clinical research period, or women of childbearing age with a positive pregnancy test before vaccination;\n12. Other conditions that may impact the subject's safety or influence the assessment of vaccine response, as determined by the investigator.",{"count":137,"type":21},[77],"This phase 1 study in China will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.",[31],[82,185,186,187,84],"shingles","varicella zoster virus","Virus-Like Particles","2025-03-26",{"date":190,"type":56},"2025-04-01",{"date":192,"type":56},"2025-03-13",{"date":194,"type":21},"2026-10",{"name":196,"class":96},"Guangzhou Patronus Biotech Co., Ltd.",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":97},"100583019","neuropathic-pain-and-traditional-medicine-syndromes-in-herpes-zoster-a-cross-sectional-study-100583019","NCT06870877","Neuropathic Pain and Traditional Medicine Syndromes in Herpes Zoster: a Cross-Sectional Study","Neuropathic Pain and Traditional Medicine Syndromes in Herpes Zoster: a Cross-Sectional Study Conducted At Le Van Thinh Hospital, Vietnam","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Clinically diagnosed with Herpes Zoster (HZ) based on European Consensus Guidelines\n* Experiencing neuropathic pain associated with HZ\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* History of chronic pain conditions unrelated to HZ\n* Receiving immunosuppressive therapy or diagnosed with immunodeficiency disorders\n* Patients who had already received antiviral or analgesic treatment before evaluation\n* Patients unable or unwilling to provide informed consent",{"count":205,"type":21},80,"This study investigates the relationship between neuropathic pain characteristics and Traditional Chinese Medicine (TCM) syndromes in patients with Herpes Zoster (HZ). The study aims to integrate objective pain assessment tools, such as the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale, with TCM diagnostic classifications to enhance individualized treatment strategies. Conducted at Le Van Thinh Hospital, Vietnam, this cross-sectional study includes 80 HZ patients, assessing their pain levels and corresponding TCM syndromes. The findings will contribute to a more comprehensive approach to pain management in Herpes Zoster.",[31,208],"Traditional Chinese Medicine (TCM)","NOT_YET_RECRUITING","2025-03-10",{"date":212,"type":56},"2025-03-11",{"date":214,"type":21},"2025-02-28",{"date":216,"type":21},"2025-05-12",{"name":218,"class":63},"Do Thanh Sang",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":226,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":97},"100577466","multimodal-nerve-block-and-pulse-radiofrequency-for-acute-herpes-zoster-pain-100577466","NCT06798662","Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain","Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain: a Prospective, Randomized, Controlled, Triple-blind Trial","Inclusion Criteria:\n\n* Presence of typical clinical manifestations of herpes zoster (shingles), including vesicular and painful rash.\n* Diagnosis of postherpetic neuralgia (PHN) lasting for more than one month, unresponsive to conventional treatment.\n* Visual Analog Scale (VAS) score ≥ 4.\n* Involvement of thoracic nerve roots.\n\nExclusion Criteria:\n\n* Refusal to provide written informed consent.\n* Inability to cooperate with study assessments.\n* History of systemic autoimmune disease, organ transplantation, or cancer.\n* Prior receipt of other invasive pain treatments, such as spinal cord stimulation.\n* Presence of a central nervous system (CNS) disorder.\n* Presence of coagulopathy.\n* Skin infection at the puncture site.\n* Pregnancy or breastfeeding.","20 Years",{"count":228,"type":21},120,[160],"The primary objective of this clinical trial is to evaluate the efficacy of liposomal bupivacaine and ropivacaine in the treatment of pain associated with herpes zoster (shingles). This trial will also assess the safety profiles of both liposomal bupivacaine and ropivacaine.\n\nThe study aims to address the following key questions:\n\nDoes nerve blockade with liposomal bupivacaine or ropivacaine reduce the required dosage of gabapentin in participants? What medical issues, if any, arise in participants undergoing paravertebral block, intercostal nerve block, RISS (Radiofrequency Intervention for Spinal Segment); or pulsed radiofrequency (PRF)? Can nerve blocks, specifically paravertebral block, intercostal nerve block, RISS; and PRF, effectively treat severe postherpetic neuralgia (PHN)? The study will compare these interventions.\n\nStudy Procedures:\n\nParticipants will:Receive ultrasound-guided nerve blocks or pulsed radiofrequency every 48 hours, for a total of 3 treatments.\n\nUndergo assessments, either in-person or via telephone, at the following time points: before therapy (baseline), on the day of treatment (Day 1), Day 7, Day 30, and Day 90 post-treatment.\n\nHave their symptoms recorded, along with their scores on the Numerical Rating Scale (NRS) and the Zoster Brief Pain Inventory (ZBPI).",[31],"2025-01-22",{"date":234,"type":56},"2025-01-29",{"date":236,"type":21},"2025-02-01",{"date":238,"type":21},"2025-06-10",{"name":240,"class":63},"Xiaguang Duan"]